Rare diseases dominate catalysts for the smallest companies
Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
Iterum’s antibiotic is far from a Sure thing
Iterum should soon find out if it has an approvable asset in the antibiotic sulopenem, but even if the group succeeds it still has a hard road ahead.
Tide turns as 2017 IPOs ramp up
Biotechs raised $3.9bn in IPOs across 2017, signalling that investor interest in new issues has returned.
